<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03008551</url>
  </required_header>
  <id_info>
    <org_study_id>Version 3.0</org_study_id>
    <nct_id>NCT03008551</nct_id>
  </id_info>
  <brief_title>Empagliflozin vs Metformin in PCOS</brief_title>
  <official_title>The Effect of Empagliflozin Versus Metformin on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome (PCOS) - a Randomised Open-label Parallel Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hull University Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hull University Teaching Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a randomised open-label parallel study involving women with polycystic ovary syndrome&#xD;
      (PCOS). The patients will be randomised either to metformin 1500mg or empagliflozin 25mg&#xD;
      daily for three months. The aim of the study is to examine the effect of empagliflozin on&#xD;
      hormonal, metabolic and cardiovascular risk markers and quality of life in women with PCOS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS) is a very common condition in women that may present with&#xD;
      irregular periods, excessive hair growth on the face and body, acne and cysts in the ovaries.&#xD;
      PCOS is also associated with increased risk of problems later in life like diabetes, high&#xD;
      cholesterol levels and heart disease.&#xD;
&#xD;
      In this study, a medication named Empagliflozin will be tested. Empagliflozin belongs to a&#xD;
      class of medicines known as SGLT-2 inhibitors. SGLT-2 stands for sodium glucose&#xD;
      co-transporter 2. Empagliflozin, in simple terms, helps in reducing high blood glucose levels&#xD;
      by increasing the amount of glucose passed in your urine. This medicine is usually used in&#xD;
      patients with type 2 diabetes and has led to improved blood pressure and weight loss in&#xD;
      addition to improving blood glucose levels.&#xD;
&#xD;
      We want to give Empagliflozin to women with PCOS to see its effect on hormones related to&#xD;
      PCOS and the risk factors for diabetes and heart disease. We will be comparing its effects to&#xD;
      metformin (another drug for diabetes) which has already been used in PCOS with very good&#xD;
      results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2017</start_date>
  <completion_date type="Actual">April 2, 2018</completion_date>
  <primary_completion_date type="Actual">April 2, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function as measured by RHI (reactive hyperaemia index).</measure>
    <time_frame>Three months treatment with either empagliflozin 25mg or metformin 1500mg daily</time_frame>
    <description>Endothelial function as measured by RHI (reactive hyperaemia index) will be assessed after three months treatment with either empagliflozin 25mg or metformin S/R 1500mg daily</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers (hsCRP)</measure>
    <time_frame>Three months treatment with either empagliflozin 25mg or metformin 1500mg daily</time_frame>
    <description>Inflammatory markers (hsCRP) will be assessed after three months treatment with either empagliflozin 25mg or metformin S/R 1500mg daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance as measured by HOMA (fasting glucose &amp; insulin)</measure>
    <time_frame>Three months treatment with either empagliflozin 25mg or metformin 1500mg daily</time_frame>
    <description>Insulin resistance as measured by HOMA (fasting glucose &amp; insulin) will be assessed after three months treatment with either empagliflozin 25mg or metformin S/R 1500mg daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Three months treatment with either empagliflozin 25mg or metformin 1500mg daily</time_frame>
    <description>Body weight will be assessed after three months treatment with either empagliflozin 25mg or metformin S/R 1500mg daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Three months treatment with either empagliflozin 25mg or metformin 1500mg daily</time_frame>
    <description>Blood pressure will be assessed after three months treatment with either empagliflozin 25mg or metformin S/R 1500mg daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>Three months treatment with either empagliflozin 25mg or metformin 1500mg daily</time_frame>
    <description>Lipid profile will be assessed after three months treatment with either empagliflozin 25mg or metformin S/R 1500mg daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal parameters including free androgen index</measure>
    <time_frame>Three months treatment with either empagliflozin 25mg or metformin 1500mg daily</time_frame>
    <description>Hormonal parameters including free androgen index will be assessed after three months treatment with either empagliflozin 25mg or metformin S/R 1500mg daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function measured by microparticles</measure>
    <time_frame>Three months treatment with either empagliflozin 25mg or metformin 1500mg daily</time_frame>
    <description>Endothelial function measured by microparticles will be assessed after three months treatment with either empagliflozin 25mg or metformin S/R 1500mg daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Questionnaire</measure>
    <time_frame>Three months treatment with either empagliflozin 25mg or metformin S/R 1500mg daily</time_frame>
    <description>Quality of life will be assessed after three months treatment with either empagliflozin 25mg or metformin S/R 1500mg daily</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Empagliflozin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive empagliflozin 25mg daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant will receive metformin 1500mg daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Each participant will receive empagliflozin 25mg daily for 3 months.</description>
    <arm_group_label>Empagliflozin group</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Each participant will receive metformin 1500mg daily for 3 months.</description>
    <arm_group_label>Metformin group</arm_group_label>
    <other_name>Glucophage SR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women, aged 18-45 years (inclusive), with confirmed diagnosis of PCOS based on&#xD;
             Rotterdam criteria.&#xD;
&#xD;
          2. Presence of both irregular periods and biochemical hyperandrogenaemia&#xD;
&#xD;
          3. Body mass index â‰¥25&#xD;
&#xD;
          4. Negative pregnancy test during screening visit and agree to use barrier contraception&#xD;
             during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-classical 21-hydroxylase deficiency, hyperprolactinaemia, Cushing's disease and&#xD;
             androgen-secreting tumours will be excluded by appropriate tests.&#xD;
&#xD;
          2. Confirmed diagnosis of diabetes or pre-diabetes.&#xD;
&#xD;
          3. Ongoing, inadequately controlled thyroid disorder (subjects on thyroid hormone&#xD;
             replacement therapy must be on stable dose for at least 3 months before screening day)&#xD;
&#xD;
          4. History or presence of malignant neoplasms within the last 5 years (except basal and&#xD;
             squamous cell skin cancer and in-situ carcinoma).&#xD;
&#xD;
          5. History or plan of any form of gastrointestinal tract surgery.&#xD;
&#xD;
          6. History of pancreatitis (Acute or Chronic).&#xD;
&#xD;
          7. Any disorder which in the opinion of the investigator might jeopardize subject's&#xD;
             safety.&#xD;
&#xD;
          8. Subjects who are on any of the following medications within 3 months of recruitment:&#xD;
&#xD;
               -  Metformin or other insulin-sensitizing medications (e.g., pioglitazone )&#xD;
&#xD;
               -  Hormonal contraceptives (e.g., birth control pills, hormone-releasing implants,&#xD;
                  etc.)&#xD;
&#xD;
               -  Anti-androgens (e.g., spironolactone, flutamide, finasteride, etc.)&#xD;
&#xD;
               -  Clomiphene citrate or estrogen modulators such as letrozole&#xD;
&#xD;
               -  GnRH modulators such as leuprolide&#xD;
&#xD;
               -  Minoxidil&#xD;
&#xD;
          9. Female who is pregnant, breast feeding or intended to become pregnant or of child&#xD;
             bearing potential not using adequate contraceptive methods.&#xD;
&#xD;
         10. eGFR&lt;60&#xD;
&#xD;
         11. Hypersensitivity to lactose&#xD;
&#xD;
         12. Severe hepatic impairment (ALT &gt;3 times ULN)&#xD;
&#xD;
         13. Women with history of recurrent urinary tract infections.&#xD;
&#xD;
         14. Haematocrit above the upper limit of normal range.&#xD;
&#xD;
         15. Have been involved in another medicinal trial (CTIMP) within the past four weeks.&#xD;
&#xD;
         16. Known hypersensitivity to the Investigational Medicinal Products or any of their&#xD;
             excipients.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thozhukat Sathyapalan, MBBS FRCP MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hull/Hull and East Yorkshire Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michael White Centre for Diabetes and Endocrinology</name>
      <address>
        <city>Hull</city>
        <state>East Yorkshire</state>
        <zip>HU3 2RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/abs/10.1111/cen.13968</url>
    <description>Publication Link</description>
  </link>
  <results_reference>
    <citation>Javed Z, Papageorgiou M, Deshmukh H, Rigby AS, Qamar U, Abbas J, Khan AY, Kilpatrick ES, Atkin SL, Sathyapalan T. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Clin Endocrinol (Oxf). 2019 Jun;90(6):805-813. doi: 10.1111/cen.13968. Epub 2019 Apr 2.</citation>
    <PMID>30866088</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 28, 2016</study_first_submitted>
  <study_first_submitted_qc>December 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

